Pharmacyclics, Inc. (NASDAQ: PCYC) will present clinical data from their HDAC Program (PCI-24781) and BTK Program (PCI-32765) at The American Society of Hematology (ASH) meeting. The company will host the presentation on December 8, 2009 at 11:00 am (ET).
The company's presentation will be broadcast via webcast on the IR section of the company's website. A replay of the presentation will be available on the company's website for 30 days.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
The presentation can also be accessed by dialing (877) 700-2945 or for international callers dial (706) 643-1591 utilizing 45071660 as the access code for both numbers.
About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
